Optiscan Imaging Ltd Launches InSpecta Into US Veterinary Market

Optiscan launches InSpecta™ device into US veterinary market

Optiscan Imaging (ASX: OIL) has launched InSpecta™, its veterinary-first microscopic imaging device, into the U.S. market following successful submission of its regulatory dossier to the U.S. Food and Drug Administration (FDA) Centre for Veterinary Medicine (CVM).

The launch marks the first of the Company’s clinical devices to have a full regulatory dossier submitted to the FDA for comment prior to formal release. It signals a pivotal shift in Optiscan’s evolution from a technology and product developer into a commercial enterprise.

InSpecta™ will be showcased at the American Veterinary Medical Association (AVMA) Convention 2026 in Anaheim, California, running 10–14 July 2026. The event gives Optiscan direct exposure to veterinary clinicians, specialists and practice decision-makers.

For investors, the significance is clear. The device establishes Optiscan’s first revenue-generating pathway into the world’s largest veterinary market.

A commercial beachhead in the world’s largest veterinary market

The launch establishes what Optiscan describes as a U.S.-based commercial beachhead. By entering veterinary medicine, the Company is extending its proprietary imaging technology beyond human healthcare into a large and expanding sector.

Demand for advanced veterinary care, including the management of complex conditions such as cancer, is driving the need for technologies that improve clinical insight and reduce diagnostic delays. According to a Grand View Research report, the U.S. veterinary services market was valued at approximately US$15.87 billion in 2024 and is projected to grow strongly through to 2033.

The scale of this opportunity underpins Optiscan’s strategy to diversify growth beyond human healthcare markets.

CEO Commentary

“The launch of Optiscan’s InSpecta™ into the U.S. veterinary market is a defining development milestone for the Company. It comes hot on the heels of our FDA CVM submission for InSpecta™, and means we can now get cracking with the commercialisation of this device, which is targeting a slice of the world’s largest veterinary healthcare market that is currently valued at more than US$15 billion,” said Dr Camile Farah, Chief Executive Officer and Managing Director.

What InSpecta™ does — microscopic imaging at the point of care

InSpecta™ is designed to address the gap between clinical examination and laboratory-based diagnostics. It delivers real-time cellular imaging within the veterinary workflow, bringing microscopic-level analysis to the point of care.

The device is built on Optiscan’s proprietary imaging platform. The Company pioneered the development of miniaturised digital endomicroscopes, small imaging instruments with spatial resolution described as more than 1,000 times that of medical CT and MRI scans.

Its compact, portable form factor is suited to specialist hospitals, general practices, mobile services and field-based care. This flexibility allows veterinarians to access advanced diagnostics across a range of tissue types and pathologies.

The practical benefits to veterinary practices include:

• Faster clinical decision-making at the point of care

• Improved workflow efficiency

• Potential new in-house, revenue-generating services

• Advanced diagnostics across a range of tissue types and pathologies

Sample images released by the Company demonstrate this clinical range, including canine mast cell tumour and canine oral melanoma tissue. In-house imaging creates a new potential revenue stream for veterinary practices while simultaneously expanding Optiscan’s addressable market.

Why the FDA milestone matters for Optiscan’s pipeline

The FDA CVM submission for InSpecta™ was, according to Optiscan, a critical value inflection point for its development and commercialisation strategy. It removed the principal regulatory hurdle to U.S. commercialisation and confirmed the device had met the requirements necessary for market entry.

The InSpecta FDA submission, lodged with the Centre for Veterinary Medicine in March 2026, confirmed Optiscan had met the regulatory requirements necessary for U.S. market entry and simultaneously opened the door to clinical reference site expansion and commercial partnership discussions.

Beyond this single product, the submission strengthens Optiscan’s regulatory capability. It provides a validated pathway and internal experience that can support future U.S. submissions across the Company’s product pipeline.

The significance spans three dimensions:

• Strategic: validates the diversification strategy and establishes a U.S. commercial beachhead

• Regulatory: removes the principal U.S. commercialisation hurdle and builds a repeatable pathway

• Commercial: delivers an FDA-compliant product with immediate U.S. market access

Optiscan has indicated more commercialisation steps are expected as it continues to progress multiple human patient studies involving its other devices. The precise timing of these steps has not been disclosed.

InVue and InForm FDA submissions for the Company’s human-use devices are tracking toward H2 CY2026, supported by a breast cancer imaging study at The Royal Melbourne Hospital that had reached the halfway recruitment mark as of June 2026 with zero adverse events across the cohort.

CEO Commentary

“The U.S. launch of InSpecta™ validates the maturity of our imaging platform and establishes a repeatable regulatory and commercial pathway for other already revealed products that utilise our proprietary imaging technology. It represents one important step in Optiscan’s transition into a commercial-stage medical technology company – and more such steps are expected to follow as we continue to progress multiple human patient studies involving our other devices,” said Dr Farah.

With its first clinical device now in market and a validated regulatory pathway established, Optiscan positions itself as a commercial-stage medical technology company. The broader product pipeline now has a demonstrated route to follow.

Don’t Miss the Next Healthcare Breakout on the ASX

Get FREE breaking ASX healthcare news delivered to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market with Big News Blast. Click the “Free Alerts” button to receive the moment market-moving healthcare announcements hit the ASX.